Centhaquin

Centhaquine (Centhaquin; PMZ-2010) is a novel agent has the potential for treatment of haemorrhagic shock. Centhaquine (Centhaquin; PMZ-2010) can augment cardiac output, reduce systemic vascular resistance in haemorrhagic models[1][2].

Product Specifications

CAS Number

[57961-90-7]

Product Name Alternative

Centhaquine; PMZ-2010

UNSPSC

12352005

Hazard Statement

H315, H319, H413

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/centhaquin.html

Purity

99.93

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

CC1=CC=CC(N(CC2)CCN2CCC3=NC4=C(C=CC=C4)C=C3)=C1

Molecular Formula

C22H25N3

Molecular Weight

331.45

Precautions

H315, H319, H413

References & Citations

[1]Srimal RC, et al. Pharmacological studies on 2- (2- (4- (3-methylphenyl) -1-piperazinyl) ethyl) quinoline (centhaquin) . I. Hypotensive activity.Pharmacol Res. 1990 May-Jun;22 (3) :319-29.|[2]Papalexopoulou K, et al. Centhaquin Effects in a Swine Model of Ventricular Fibrillation: Centhaquin and Cardiac Arrest.Heart Lung Circ. 2017 Aug;26 (8) :856-863.